BibTex RIS Kaynak Göster

Treatment Options in Management of Psoriasis

Yıl 2015, Cilt: 24 Sayı: 3, 339 - 347, 14.09.2015
https://doi.org/10.17827/aktd.72019

Öz

Psoriasis is a chronic dermatosis characterized by erythema, silvery-white squamous, sharp-edged papules and plaques. Along with skin, it can also immerse towards supplements of skin like nail and joints. There is no curative treatment for this disease which has no known certain etiology. The management of the disease is closely related with severity of the disease. Patient’s physical, psychosocial status and general health should be taken into consideration while determining most appropiate treatment approach.

Kaynakça

  • Gülekon A. Psöriasis ve benzeri dermatozlar. In: Dermatoloji, 3. Baskı (Eds Y Tüzün, MA Gürer, S Serveroğlu, O Sungur, LA Aksungur):745-60. İstanbul, Nobel Tıp Kitapevi. 2008.
  • Ergun T. Systemic treatment of psoriasis: rational use of therapeutics and controversial issues. Turkish Journal of Dermatology. 2007;1:8-14.
  • Duman D. Psöriaziste topikal tedaviler. Türkiye Klinikleri J Dermatol-Special Topics. 2008;1:55-62.
  • Lebwohl M, Ali S. Treatment of psoriasis. Part 1 Topical therapy and phototherapy J Am Acad Dermatol. 2001;45:487-98.
  • Bruce S, Epinette WW, Funicella. Comparative study of calcipotriene oinment and flucinonide oinment in the treatment of psoriasis J Am Acad Dermatol. 1994;31:755-9.
  • Volden G, Bjonberg A, Tegner E. Short contact treatment at home with Micanol. Acta Derm Venereol Suppl (Stockh). 1992;172:20-2.
  • Onsun N. Psoriasis tedavi yöntemleri ve algoritmik yaklaşım. Türkderm. 2008;42:31–41.
  • Braun-Falco O, Plewig G, Wolff HH, Burgdorf WHC: Dermatology. 2. edition, Berlin, Springer- Verlag, 2000.
  • Kaya Tİ. Psoriyazisin topikal tedavisi. T Klin Dermatol. 2005;13:68-73.
  • Gudjonsson JE, Elder JT. Psoriasis. In: Fitzpatrick’s Dermatology in General Medicine, 7th ed (Eds K Wolff, LA Goldsmith, SI Katz, BA Gilchrest, AS Paller, DJ Leffell):169-94. New York, McGraw Hill, 2008.
  • Özarmağan G, Babuna G. Psoriaziste klasik sistemik tedaviler ve hasta seçimi. Türkiye Klinikleri J Dermatol-Special Topics. 2008;1:68-76.
  • Smith CH, Barker JNWN. Psoriasis and its management. BMJ. 2006;333:380-4.
  • Ho VC. The use of ciclosporine in psoriasis: a clinical review. Br J Dermatol. 2004;150:1-10.
  • Mehlis SL, Gordon KB. The immunology of psoriasis and biologic immunotherapy. J Am Acad Dermatol. 2003;49:44-50.
  • Menter A, Gottlieb A, Feldman SR, Van Voorhees AS, Leonardi CL, Gordon KB et al. Guidelines of care for the management of psoriasis and psoriatic arthritis. Section 1. Overview of psoriasis and guidelines of care for the treatment of psoriasis with biologics. J Am Acad Dermatol. 2008;58:826-50.
  • Smith CH, Anstey A, Barker JN . British Association of dermatologists guidelines for use of biologic interventions in psoriasis: 2005. Br J Dermatol. 2005;153:486-97.
  • Thomas VD, Yang FC, Kvedar JC. Biologics in psoriasis: a quick reference guide. J Am Acad Dermatol. 2005;53:346-51.
  • Graves JE, Nunley K, Heffernan MP. Off-label uses of biologics in dermatology:rituximab, omalizumab, infliximab, and alefacept . J Am Acad Dermatol. 2007;56:55-79.
  • Feldman SR, Gordon KB, Bala M . İnfliximab treatment results in significant improvement in the quality of life of patients with severe psoriasis: a double-blind, placebo-controlled trial. Br J Dermatol. 2005:152:954-60.
  • Mazur M, Kerczewski J, Lodyga M, Zeba R, Adamski Z. Inhibitors of phosphodiesterase 4 (PDE4): a new therapeutic option in the treatment of psoriasis vulgaris and psoriatic arthritis. J Dermatology Treat. 2014; doi: 10.3109/096546634.2014.991267.
  • Kutlubay Z, Karakuş Ö, Engin B, Serdaroğlu S. Psoriasis: klinik tiplerine göre tedavi yaklaşımı. Dermatoz. 2012;3:33-8.
  • Correspondence Address / Yazışma Adresi

Psöriazisin Yönetiminde Tedavi Seçenekleri

Yıl 2015, Cilt: 24 Sayı: 3, 339 - 347, 14.09.2015
https://doi.org/10.17827/aktd.72019

Öz

Psöriazis eritemli, gümüşümsü-beyaz skuamlı, keskin sınırlı papül ve plaklarla karakterize kronik seyirli bir dermatozdur. Derinin yanında, deri eki olan tırnak ve eklemlerde de tutulabilir. Etiyolojisi net olarak bilinmeyen hastalığın küratif bir tedavisi yoktur. Tedavi yaklaşımı hastalığın şiddetine ek olarak, hastanın fiziksel ve psikososyal durumu, genel sağlığının da göz önüne alınıp en uygun yöntemin belirlenmesini içerir.

Kaynakça

  • Gülekon A. Psöriasis ve benzeri dermatozlar. In: Dermatoloji, 3. Baskı (Eds Y Tüzün, MA Gürer, S Serveroğlu, O Sungur, LA Aksungur):745-60. İstanbul, Nobel Tıp Kitapevi. 2008.
  • Ergun T. Systemic treatment of psoriasis: rational use of therapeutics and controversial issues. Turkish Journal of Dermatology. 2007;1:8-14.
  • Duman D. Psöriaziste topikal tedaviler. Türkiye Klinikleri J Dermatol-Special Topics. 2008;1:55-62.
  • Lebwohl M, Ali S. Treatment of psoriasis. Part 1 Topical therapy and phototherapy J Am Acad Dermatol. 2001;45:487-98.
  • Bruce S, Epinette WW, Funicella. Comparative study of calcipotriene oinment and flucinonide oinment in the treatment of psoriasis J Am Acad Dermatol. 1994;31:755-9.
  • Volden G, Bjonberg A, Tegner E. Short contact treatment at home with Micanol. Acta Derm Venereol Suppl (Stockh). 1992;172:20-2.
  • Onsun N. Psoriasis tedavi yöntemleri ve algoritmik yaklaşım. Türkderm. 2008;42:31–41.
  • Braun-Falco O, Plewig G, Wolff HH, Burgdorf WHC: Dermatology. 2. edition, Berlin, Springer- Verlag, 2000.
  • Kaya Tİ. Psoriyazisin topikal tedavisi. T Klin Dermatol. 2005;13:68-73.
  • Gudjonsson JE, Elder JT. Psoriasis. In: Fitzpatrick’s Dermatology in General Medicine, 7th ed (Eds K Wolff, LA Goldsmith, SI Katz, BA Gilchrest, AS Paller, DJ Leffell):169-94. New York, McGraw Hill, 2008.
  • Özarmağan G, Babuna G. Psoriaziste klasik sistemik tedaviler ve hasta seçimi. Türkiye Klinikleri J Dermatol-Special Topics. 2008;1:68-76.
  • Smith CH, Barker JNWN. Psoriasis and its management. BMJ. 2006;333:380-4.
  • Ho VC. The use of ciclosporine in psoriasis: a clinical review. Br J Dermatol. 2004;150:1-10.
  • Mehlis SL, Gordon KB. The immunology of psoriasis and biologic immunotherapy. J Am Acad Dermatol. 2003;49:44-50.
  • Menter A, Gottlieb A, Feldman SR, Van Voorhees AS, Leonardi CL, Gordon KB et al. Guidelines of care for the management of psoriasis and psoriatic arthritis. Section 1. Overview of psoriasis and guidelines of care for the treatment of psoriasis with biologics. J Am Acad Dermatol. 2008;58:826-50.
  • Smith CH, Anstey A, Barker JN . British Association of dermatologists guidelines for use of biologic interventions in psoriasis: 2005. Br J Dermatol. 2005;153:486-97.
  • Thomas VD, Yang FC, Kvedar JC. Biologics in psoriasis: a quick reference guide. J Am Acad Dermatol. 2005;53:346-51.
  • Graves JE, Nunley K, Heffernan MP. Off-label uses of biologics in dermatology:rituximab, omalizumab, infliximab, and alefacept . J Am Acad Dermatol. 2007;56:55-79.
  • Feldman SR, Gordon KB, Bala M . İnfliximab treatment results in significant improvement in the quality of life of patients with severe psoriasis: a double-blind, placebo-controlled trial. Br J Dermatol. 2005:152:954-60.
  • Mazur M, Kerczewski J, Lodyga M, Zeba R, Adamski Z. Inhibitors of phosphodiesterase 4 (PDE4): a new therapeutic option in the treatment of psoriasis vulgaris and psoriatic arthritis. J Dermatology Treat. 2014; doi: 10.3109/096546634.2014.991267.
  • Kutlubay Z, Karakuş Ö, Engin B, Serdaroğlu S. Psoriasis: klinik tiplerine göre tedavi yaklaşımı. Dermatoz. 2012;3:33-8.
  • Correspondence Address / Yazışma Adresi
Toplam 22 adet kaynakça vardır.

Ayrıntılar

Birincil Dil İngilizce
Bölüm Derleme
Yazarlar

Gülbahar Saraç Bu kişi benim

Tuba Koca

Hatice Demirdağ Bu kişi benim

Yayımlanma Tarihi 14 Eylül 2015
Yayımlandığı Sayı Yıl 2015 Cilt: 24 Sayı: 3

Kaynak Göster

AMA Saraç G, Koca T, Demirdağ H. Treatment Options in Management of Psoriasis. aktd. Eylül 2015;24(3):339-347. doi:10.17827/aktd.72019